

**Freedom of Information Request**

**Ref: 22-646**

17 November 2022

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

- We can confirm that we hold some of the information you are requesting

**In the past 3 months, how many Breast Cancer patients (at any stage) were treated with:**

**Abemaciclib monotherapy 0**

**Aromatase inhibitor monotherapy (e.g. anastrozole, exemestane, letrozole)**

We do not hold this information. We are unable to supply this data as these drugs are usually prescribed by the GP rather than the hospital.

**Tamoxifen monotherapy**

We do not hold this information. We are unable to supply this data as these drugs are usually prescribed by the GP rather than the hospital.

**Abemaciclib + Tamoxifen 0**

**In the past 3 months, how many early/locally advanced Breast Cancer (Stages 1 to 3B) patients were treated with:**

**Abemaciclib + Aromatase inhibitor (e.g. anastrozole, exemestane, letrozole) \***

**Taxane and/or Anthracycline (monotherapy or in combination) 8**

**Any other active systemic anti cancer therapy**

Our SACT e-prescribing system uses the TNM staging system and it would take longer than 18 hours to translate this to the staging requested for all the relevant patients. Please note, the Trust does not hold the data in a format that would enable us to fully respond to your request to the level of detail required and a manual trawl for this information would significantly exceed the 18 hours limit set down by the FOI as the reasonable limit. Section 12 of the FOIA provides that we are not obliged to spend in excess of 18 hours in any sixty-day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

Please note: Where the figures are between 1 and 5, this has been denoted by \*. Due to the low numbers, we have considered that there is the potential for individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. The Trust therefore finds that the Section 40(2) exemption contained within the Freedom of information Act 2000 is engaged. (Section 40 is the exemption for personal information).

**How many patients have been treated for Triple Negative Breast Cancer (any stage) in the past 3 months with the following systemic anti cancer therapies:**

**Anthracycline (e.g. doxorubicin or epirubicin) as a single agent**

We do not hold this information. We do not record ER/PR/HER2 status in our SACT e-prescribing system so cannot provide the requested information for any drugs with indications other than triple negative disease.

**Atezolizumab +Nab-paclitaxel/Paclitaxel \***

**Pembrolizumab 15**

**Sacituzumab Govitecan 11**

**Parp Inhibitors (Olaparib/Talazoparib)**

We do not hold this information. We do not record ER/PR/HER2 status in our SACT e-prescribing system so cannot provide the requested information for any drugs with indications other than triple negative disease.

**Eribulin as a single agent or in combination**

We do not hold this information. We do not record ER/PR/HER2 status in our SACT e-prescribing system so cannot provide the requested information for any drugs with indications other than triple negative disease.

**Capecitabine as a single agent**

We do not hold this information. We do not record ER/PR/HER2 status in our SACT e-prescribing system so cannot provide the requested information for any drugs with indications other than triple negative disease.

**Platinum (e.g. carboplatin or cisplatin) as a single agent**

We do not hold this information. We do not record ER/PR/HER2 status in our SACT e-prescribing system so cannot provide the requested information for any drugs with indications other than triple negative disease.

**Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent**

We do not hold this information. We do not record ER/PR/HER2 status in our SACT e-prescribing system so cannot provide the requested information for any drugs with indications other than triple negative disease.

**Taxane and/or Anthracycline in combination**

We do not hold this information. We do not record ER/PR/HER2 status in our SACT e-prescribing system so cannot provide the requested information for any drugs with indications other than triple negative disease.

**Any other active systemic anti-cancer therapy**

We do not hold this information. We do not record ER/PR/HER2 status in our SACT e-prescribing system so cannot provide the requested information for any drugs with indications other than triple negative disease.

Please note: Where the figures are between 1 and 5, this has been denoted by \*. Due to the low numbers, we have considered that there is the potential for individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. The Trust therefore finds that the Section 40(2) exemption contained within the Freedom of information Act 2000 is engaged. (Section 40 is the exemption for personal information).

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Data Protection Officer  
University Hospitals Bristol and Weston NHS Foundation Trust  
Trust Headquarters  
Marlborough Street  
Bristol  
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because

information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

**Freedom of Information Team**  
**University Hospitals Bristol and Weston NHS Foundation Trust**